NCT01051102View on ClinicalTrials.gov

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec/insulin aspart

Single dose of 0.5 U/kg body weight injected s.c. (under the skin)

DRUG

biphasic insulin aspart 30

Single dose of 0.5 U/kg body weight injected s.c. (under the skin)

Trial Locations (1)

130-0004

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY